Press

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Aug 10 • 5 min read

Quick Take: Revive provides an update on their psychedelic product development pipeline. One key component of their research pipeline is the research of the use of psilocybin to treat traumatic brain injury and stroke. Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for…

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

Aug 10 • 4 min read

Quick Take: MindMed has appointed Dr. Robert Dworkin, a professor with over 35 years of conducting clinical research on pain, to its scientific advisory board. MindMed (NASDAQ: MNMD) (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years…

Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology

Aug 9 • 4 min read

Quick Take: Ketamine one has partnered with a virtual reality company to begin its scent-based VR therapy platform. KetamineOne Capital Limited (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce it has signed an exclusive agreement for the use of virtual…

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

Aug 6 • 2 min read

Quick Take: Compass Pathways will announce their second quarter financial results on August 11. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business…

PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease

Aug 5 • 4 min read

Quick Take: PharmaDrug has formed a partnership with a biotechnology institute to research DMT therapy for eye diseases. PharmaDrug Inc. (CSE: PHRX), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435